GNF362 is primarily utilized in the field of biomedical research, particularly in the study and development of treatments for diseases related to protein misfolding. It functions as a potent inhibitor of the heat shock protein 90 (HSP90), which plays a crucial role in the proper folding and function of various client proteins involved in cancer, neurodegenerative disorders, and other pathological conditions. By inhibiting HSP90, GNF362 helps researchers understand the mechanisms of protein misfolding and aggregation, providing insights into potential therapeutic strategies. Its application extends to preclinical studies where it is used to evaluate the efficacy of targeting HSP90 in disease models, aiding in the discovery of novel drug candidates for conditions such as Alzheimer's disease, Parkinson's disease, and certain types of cancer.